Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Compared to Estimates, Catalyst (CPRX) Q3 Earnings: A Look at Key Metrics
07:01pm, Wednesday, 05'th Nov 2025
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics comp
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings and Revenue Estimates
06:46pm, Wednesday, 05'th Nov 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
04:06pm, Wednesday, 05'th Nov 2025
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Gu
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
04:03pm, Tuesday, 04'th Nov 2025
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday
03:02am, Tuesday, 04'th Nov 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) is projected to issue its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
08:03am, Monday, 03'rd Nov 2025
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline
11:01am, Wednesday, 29'th Oct 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DekaBank Deutsche Girozentrale Purchases 12,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
04:12am, Sunday, 26'th Oct 2025
DekaBank Deutsche Girozentrale boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Secu
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Friday, 24'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
08:03am, Wednesday, 22'nd Oct 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:50am, Friday, 10'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
08:03am, Thursday, 09'th Oct 2025
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and c
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 08'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
08:03am, Wednesday, 01'st Oct 2025
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licens
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
10:46am, Monday, 22'nd Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
